FGF23, Hypophosphatemia, and Emerging Treatments
Open Access
- 18 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 3 (8) , e10190
Abstract
FGF23 is an important hormonal regulator of phosphate homeostasis. Together with its co‐receptor Klotho, it modulates phosphate reabsorption and both 1α‐hydroxylation and 24‐hydroxylation in the renal proximal tubules. The most common FGF23‐mediated hypophosphatemia is X‐linked hypophosphatemia (XLH), caused by mutations in the PHEX gene. FGF23‐mediated forms of hypophosphatemia are characterized by phosphaturia and low or low‐normal calcitriol concentrations, and unlike nutritional rickets, these cannot be cured with nutritional vitamin D supplementation. Autosomal dominant and autosomal recessive forms of FGF23‐mediated hypophosphatemias show a similar pathophysiology, despite a variety of different underlying genetic causes. An excess of FGF23 activity has also been associated with a number of other conditions causing hypophosphatemia, including tumor‐induced osteomalacia, fibrous dysplasia of the bone, and cutaneous skeletal hypophosphatemia syndrome. Historically phosphate supplementation and therapy using analogs of highly active vitamin D (eg, calcitriol, alfacalcidol, paricalcitol, eldecalcitol) have been used to manage conditions involving hypophosphatemia; however, recently a neutralizing antibody for FGF23 (burosumab) has emerged as a promising treatment agent for FGF23‐mediated disorders. This review discusses the progression of clinical trials for burosumab for the treatment of XLH and its recent availability for clinical use. Burosumab may have potential for treating other conditions associated with FGF23 overactivity, but these are not yet supported by trial data. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.Keywords
This publication has 97 references indexed in Scilit:
- FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortalityJournal of Clinical Investigation, 2012
- Chronic Inhibition of ERK1/2 Signaling Improves Disordered Bone and Mineral Metabolism in Hypophosphatemic (Hyp) MiceEndocrinology, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in miceProceedings of the National Academy of Sciences, 2011
- Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivoBone, 2011
- A clinician's guide to X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2011
- Calcitonin Administration in X-Linked HypophosphatemiaNew England Journal of Medicine, 2011
- Autosomal-Recessive Hypophosphatemic Rickets Is Associated with an Inactivation Mutation in the ENPP1 GeneThe American Journal of Human Genetics, 2010
- The parathyroid is a target organ for FGF23 in ratsJournal of Clinical Investigation, 2007
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006